Dr. Claude Piché
Co-Creator and CEO
"Glucagon is a really great drug, but today’s devices that deliver it in a rescue situation are too difficult to use—we need to make it really easy to deliver, even in the most stressful situations."
Claude is leading the development of our solution. He has over 25 years of experience in developing and commercializing pharmaceuticals, vaccines, and diagnostics, including more than 12 years where he focused on diabetes therapeutics and hypoglycemia-related technologies. He has worked at large companies such as Merck, as well as start-up biopharmaceutical companies where he had roles in research, regulatory affairs, marketing, and operations.
Co-Creator and Chairman
"Our success and legacy as a diabetes-focused company will be judged by our impact on expanding the community of people who don’t actually live with diabetes themselves but become more comfortable dealing with severe hypoglycemia rescue."
Robert is passionate about reducing the burdens of dealing with diabetes. He has a long history of spreading the “be prepared” message as it relates to hypoglycemia and is a strong advocate for simplifying hypoglycemia rescue. He has over 25 years of experience as an entrepreneur, investor, and board leader in the diabetes field. Robert’s first diabetes company, CanAm Care, was built in the 1990s and created Dex4®, the leading brand of nonprescription hypoglycemia treatment products. Robert’s focus on bringing innovative ideas to diabetes stems from the experience of raising his two sons, both of whom have type 1 diabetes.
Chief Commercial Officer
"Hypoglycemia is the unspoken ‘second diagnosis’ that comes with diabetes, and a constant threat in everyday life."
Martin brings a truly unique perspective to our mission that is rooted in his professional and personal connections to diabetes. He has more than 15 years of experience in the pharmaceutical and medical device industry. At companies including GlaxoSmithKline, he held leadership positions in a variety of commercial roles covering several therapeutic areas, including diabetes management. Martin is either on the board of, or an advisor to, several diabetes-related organizations, including the Behavioral Diabetes Institute and American Youth Understanding Diabetes Abroad. He authored a chapter in the book, “Successful Men With Diabetes.” Martin has lived with type 1 diabetes for over 25 years.
Robert “Boz” Coburn
Chief Financial Officer
"Beyond the heavy psychosocial burden hypoglycemia places on insulin users and those that touch their lives, we must also be cognizant of the financial burden it places on our healthcare system. We need to have better solutions to keep people out of ambulances and emergency rooms."
Boz brings 30 years of experience in finance, venture capital, as well as business and commercial development. His early career began in public accounting with PriceWaterhouseCoopers after which he transitioned to the pharmaceutical industry, including rewarding positions with Sanofi and several small companies recognized for bringing important healthcare innovations to people in need. Boz is a CPA and holds an MBA from The Haub School of Business, St. Joseph’s University.
Myriam Triest, Ph.D.
Director, Product Development
Patricia Stotland, B.Sc
Director, Regulatory Affairs
Director of Operations
Hélène Dulude, B.Pharm., Ph.D.
Director, Clinical Development
Administrative and Accounting Assistant
Ronith Afar, Ph.D.
Director, Regulatory Affairs
Commercial Planning Manager
Assistant Bookkeeper and Accounts Payable
Manager, Quality Assurance